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ABSTRACT
CHD8 is a chromatin remodeling ATPase of
the SNF2 family. We found that depletion of
CHD8 impairs cell proliferation. In order to identify
CHD8 target genes, we performed a transcriptomic
analysis of CHD8-depleted cells, finding out
that CHD8 controls the expression of cyclin E2
(CCNE2) and thymidylate synthetase (TYMS), two
genes expressed in the G1/S transition of the cell
cycle. CHD8 was also able to co-activate the
CCNE2 promoter in transient transfection experi-
ments. Chromatin immunoprecipitation experiments
demonstrated that CHD8 binds directly to the 5’
region of both CCNE2 and TYMS genes.
Interestingly, both RNA polymerase II (RNAPII)
and CHD8 bind constitutively to the 5’ promoter-
proximal region of CCNE2, regardless of the cell-
cycle phase and, therefore, of the expression of
CCNE2. The tandem chromodomains of CHD8 bind
in vitro specifically to histone H3 di-methylated
at lysine 4. However, CHD8 depletion does not
affect the methylation levels of this residue.
We also show that CHD8 associates with the elon-
gating form of RNAPII, which is phosphorylated
in its carboxy-terminal domain (CTD). Furthermore,
CHD8-depleted cells are hypersensitive to drugs
that inhibit RNAPII phosphorylation at serine 2, sug-
gesting that CHD8 is required for an early step of the
RNAPII transcription cycle.
INTRODUCTION
The packaging of eukaryotic DNA into nucleosomes
and higher order structures represents an obstacle for
transcription initiation and elongation (1,2). Diﬀerent
nuclear machineries are responsible for the reorganization
of interactions within the chromatin which allows speciﬁc
and general transcription factors to gain access to their
targets in the DNA and to carry out gene transcription
in a tightly regulated manner. A speciﬁc type of chromatin
remodeling machine uses the energy of ATP hydrolysis to
alter interactions between histones and DNA within the
nucleosome (3). It is believed that ATP-dependent chro-
matin remodeling machines (CRMs) are able to move
nucleosomes, reorganize their structure and composition
or even remove them (4). All ATP-dependent CRMs con-
tain a DNA-dependent ATPase of the SNF2 family, which
is considered as the catalytic subunit responsible for the
remodeling. According to the sequence homology of their
conserved ATPase domains, SNF2 proteins have been
classiﬁed into distinct subfamilies such as SWI2/SNF2,
ISWI, CHD1, Mi-2, CHD7, INO80, etc. (5).
Many authors have shown how ATP-dependent CRMs
positively or negatively aﬀect the formation of the tran-
scription pre-initiation complex (6–12) but, on the con-
trary, little is known about how these enzymes may
aﬀect subsequent steps of the transcription cycle such as
elongation or termination. The RNA polymerase II
(RNAPII) complex is very ineﬃcient at transcribing chro-
matinized templates in vitro (1). In fact, biochemical stu-
dies have revealed that nucleosomes represent a strong
barrier against elongation, so that RNAPII stops at cer-
tain arrest sites near them, becoming blocked in a cataly-
tically inactive state (13,14). Two elongation complexes,
FACT (facilitates chromatin transcription) (15) and
CTEA (chromatin transcription enabling activity) (16),
have been shown to stimulate RNAPII passage through
a nucleosome. However, whether ATP-dependent chro-
matin remodeling enzymes are also required to remodel
nucleosomes during RNAPII elongation is still unclear.
In this respect, Kingston and colleagues reported that
the SWI/SNF complex, one of the best characterized
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ATP-dependent CRMs, which contains an ATPase of
the SWI2/SNF2 subfamily, enhances HSF1-mediated
stimulation of promoter-proximal paused RNAPII
in vitro (17). Furthermore, Carey et al. also demonstrated
a role for SWI/SNF and the related RSC complex in
elongation in vitro, as they are able to release RNAPII
from the blockade caused by a positioned nucleosome
(18). Despite these facts, so far there is no clear evi-
dence in vivo for a role of SWI/SNF-type CRMs in
elongation.
On the other hand, CHD1 (chromodomain-ATPase/
helicase-DNA-binding domain 1), another SNF2-like
ATPase belonging to the so called CHD1 subfamily,
does appear to function in both elongation and termina-
tion. In yeast and ﬂies CHD1 associates with highly active
transcription sites (19,20). Furthermore, CHD1 mutant
alleles in yeast are sensitive to 6-azauracil (21) and genet-
ically interact with Set2 and Spt5, both involved in elon-
gation (20,22). Finally, CHD1 physically associates with
factors involved in elongation such as the polymerase
II-associated complex (PAF), DSIF (DRB-sensitivity-
inducing factor) and FACT (20,23,24). These results
strongly indicate that CHD1 works as an elongation
factor in vivo, although very little mechanistic data had
been provided until recently, when Konev et al. (25)
showed that Drosophila CHD1 is involved in histone
H3.3 replacement in the transcriptionally silent male pro-
nucleus. Moreover, the Schizosaccharomyces pombe
homolog of CHD1, Hrp1, has been shown to function
in loading of the centromere-speciﬁc H3 variant CENP-
A (26). Therefore, CHD1 also may have a general role in
replication-independent nucleosome assembly. The con-
nection between this CHD1 function and its role in
elongation remains unknown.
In addition to CHD1, there are other eight CHD pro-
teins in mammalian cells, which are classiﬁed into three
subfamilies called CHD1 (CHD1 and CHD2), Mi-2
(CHD3 to CHD5) and CHD7 (CHD6 to CHD9) subfa-
milies (5,27). Here we have investigated the role of CHD8
in transcription. In addition to the typical helicase-like
domain that characterizes the SNF2 family, CHD8
contains two tandem chromodomains within the amino-
terminal half of the protein. Chromodomains are evolu-
tionary conserved motifs involved in interactions with
DNA, RNA or methylated lysines (28). Moreover,
CHD8 also contains a SANT domain and two BRK
domains with unclear functions. CHD8 has been
shown to interact with CTCF and is required for CTCF-
dependent insulator activity (29). Recently, it has also
been shown that CHD8 interacts with the human proteins
Staf and b-catenin and contributes to regulate U6 and
b-catenin-dependent gene transcription (30,31). We
found that CHD8 is required for cell proliferation.
CHD8 positively controls the expression of cyclin E2
(CCNE2) and thymidylate synthetase (TYMS), two
genes speciﬁcally expressed in the G1/S transition.
Furthermore, CHD8 associates constitutively with the
promoter and the transcribed 50 region of its target
genes and interacts with elongating RNAPII, suggesting
a role for this protein in transcription elongation.
MATERIALS AND METHODS
Cell culture, growth curves and cell-cycle analyses
All cells were maintained in Dulbecco’s modiﬁed Eagle’s
medium (DMEM) supplemented with 7% fetal bovine
serum, 100 units/ml penicillin and 100 mg/ml streptomycin,
and were cultivated in a 378C incubator with 5% CO2. For
cell growth analysis, 2 105 C33KD1, C33KD2 and
HeLaKD1 cells were seeded in 10 cm plates, with or with-
out 2 mg/ml doxycycline (Sigma). At the indicated times
cells were collected and counted using a Neubauer haemo-
cytometer. Cell-cycle analysis was carried out using BD
FACSCalibur ﬂow cytometer (BD Biosciences), as pre-
viously described (32). When required cultures were trea-
ted with Flavopiridol (Sanoﬁ-Aventis) or DRB (Sigma)
at the indicated ﬁnal concentration. Stock solution of
Flavopiridol 10mM was prepared in DMSO. For BrdU
cell proliferation assays, cells were labeled with 10mM
BrdU during 15min. BrdU incorporation was detected
using the 5-bromo-20-deoxy-uridine Labeling and
Detection Kit I (Roche).
Cells were synchronized by double thymidine blocking
as previously described (33), except that samples were
taken at the following times after blocking release:
t=0h (G1/S phase), t=4h (S phase), t=14h (early
G1 phase) and t=18h (late G1 phase). The cell-cycle
stage of each population was determined by ﬂow cytome-
try analysis.
Plasmid constructs
To make pTER-CHD8-1 and pTER-CHD8-2, annealed
gene-speciﬁc oligonucleotides encoding shRNA1 or
shRNA2 (Supplementary Table S2) were ligated into
pTER (34) and pSUPER vectors (35) previously digested
with BglII and HindIII.
The pRSV-CHD8 expression vector containing the
CHD8 protein (2581 amino acids) was constructed as
follows: ﬁrst, a BlpI-NotI fragment from pBC SK (+)-
KIAA1564 (provided by the Kazusa DNA Research
Institute, Japan) was cloned into a pTriplEx2 (BD
Biosciences) containing the EST AV762074 (provided by
the Chinese National Human Genome Center, China) to
constitute pTriplEx2-CHD8. After that, a PmlI restriction
site was inserted before the CHD8 sequence using stan-
dard PCR techniques and, ﬁnally, a PmlI-NotI fragment
from the former construct was cloned into a pAdRSV-Sp
(36) derivative containing an in-frame FLAG epitope, and
previously linearized with PmlI and NotI.
For Luciferase reporter assays, pCycE2 was constructed
by inserting a PCR fragment ranging from nucleotide
960 to nucleotide +60 of CCNE2 gene into pCycE
(37) previously digested with HindIII and NotI.
To make pGEX-CD1, pGEX-CD2, pGEX-CD1+
CD2, and pGEX-CD1+mutCD2, pGEX-mutCD1+
CD2 fragments encoding CHD8 CD1 (residues 629–
715), CD2 (residues 710–785), CD1+CD2 (residues
629–785), CD1+mutCD2 (residues 629–785, W751L,
Y756L), and mutCD1+CD2 (residues 629–785, Y672L,
Y675L, Y677L), were cloned into a pGEX-4T-2 vector
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(GE Healthcare) using standard PCR techniques. All con-
structs were veriﬁed by DNA sequencing.
Generation of inducible knockdown cell lines
To generate inducible shRNA CHD8 knockdown cell
lines, C33A and HeLa cells were co-transfected with
pCDNA6TR (Invitrogen) and pTER-CHD8-1. Resistant
clones were selected in the presence of 100 mg/ml Zeocin
and 5 mg/ml Blasticidin, and tested for their ability to
down-regulate CHD8 by immunoblotting, at diﬀerent
times after the addition of 2 mg/ml Dox.
ChIP assays
ChIP assays were basically performed as described by
Upstate/Millipore (http://www.millipore.com/techpubli
cations/tech1/mcproto407). ChIP data are the average of
12–18 real-time PCR quantiﬁcations from two to three
independent experiments. Real-time PCRs were per-
formed in an Applied Biosystems 7500 FAST Real-Time
PCR System, using the Applied Biosystems Power SYBR
Green Master Mix and protocols. ChIP was quantiﬁed
relative to inputs using the method described in (38).
Speciﬁc primers for CCNE2, TYMS and b-Actin
(ACTB) were designed using the Primer Express 3.0 soft-
ware (Applied Biosystems) and are described in the
Supplementary Table S2.
Antibodies used in ChIP assays include polyclonal
a-CHD8 (30ml per sample), a-H3K4me3, a-H3K4me2
(Upstate/Millipore) (5 ml per sample) and a-RNAPII
N-20 (Santa Cruz Biotechnologies) (5ml per sample).
Antibodies, immunoblotting and immunoprecipitations
Immunobloting experiments were carried out as pre-
viously described (39). Co-immunoprecipitations were
carried out as described (40). To detect CHD8, a rabbit
polyclonal serum raised against a GST fusion protein
containing human CHD8 residues 16–227 was
used. Commercial antibodies used for immunoblotting
include a-CCNE2 (Cell Signalling Technology), a-E2F1
(KH95), a-SPT5 (H-300), a-BRAF35 (4.21), a-RNAPII
(N-20) (Santa Cruz Biotechnology), a-Ser5-P-RNAPII
(CTD4H8, Upstate-Millipore), a-RNAPIIa (8WG16),
a-Ser2-P-RNAPII (H5) and a-Ser5-P-RNAPII (H14)
(Covance).
Gene-expression analysis
RNA was isolated using the RNeasy Mini kit (Qiagen).
cDNA was synthesized from 3 mg of total RNA with the
SuperScript First-Strand Synthesis system for RT–PCR
(Invitrogen). One-twentieth of the reaction was used for
PCR ampliﬁcation with speciﬁc primers spanning an
intron as a control for DNA contamination. To keep
the ampliﬁcation within the quantitative range, the
number of cycles, usually 12–25, was set up for each
experiment. Products were detected by Southern blot,
using an InstantImager Electronic Autoradiography
device (Packard Instrument) for quantiﬁcation of radio-
active areas. Gene-speciﬁc primers used in RT–PCR
experiments are described in the Supplementary Table S2.
Microarray gene-expression analysis
Total RNA samples coming from C33KD2 cells cultured
for 48 h either with or without 2 mg/ml doxycycline were
used to generate complementary RNA labeled either
with Cyanine 3 or Cyanine 5 with the Agilent Low
RNA Input Fluorescent Linear Ampliﬁcation Kit
(Agilent Technologies). Dye incorporation was deter-
mined with a NanoDrop spectrophotometer. Once label-
ing was completed, both samples were combined and
hybridized to a whole human genome Agilent 44K
60-mer Oligo Microarray (Agilent Technologies) accord-
ing to manufacturer’s instructions. The experiment was
performed in triplicate in order to achieve statistical sig-
niﬁcance. The microarrays were scanned on an Agilent
G2565 scanner (Agilent Technologies) and images were
extracted and quality assessed with the Agilent Feature
Extraction software (Agilent Technologies). Data from
the three individual hybridizations were normalized
using the RMA algorithm, and the data were then further
analyzed using the microarray software package
Genespring GX 7.3 software (Agilent Technologies).
Microarray data have been deposited in the GEO (Gene
Expression Omnibus) database with the accession number
GSE11422.
Luciferase reporter assays
For luciferase reporter assays, 2 105 COS-7 cells per
well were seeded in six-well plates and co-transfected
with 200 ng of the luciferase reporter vectors, pCycE2,
or pMMTV-Luc, and increasing quantities of pRSV-
CHD8, by using Fugene-6 (Roche). Luciferase activity
was determined 36 h after transfection with Lysis
Solution 1 (Promega), Luciferase Substrate (Promega)
and a GloMax 20/20 luminometer (Promega), following
the manufacturer’s instructions. All transfections were
normalized by measuring b-galactosidase activity of the
samples. Data are the average of at least three indepen-
dent experiments and error bars indicate standard
deviation.
Peptide binding assays
Sequences encoding CHD8 CD1 (residues 629–715), CD2
(residues 710–785) CD1+CD2 (residues 629–785),
CD1+mutCD2 (residues 629–785, W751L, Y756L) and
mutCD1+CD2 (residues 629–785, Y672L, Y675L,
Y677L) were expressed as GST fusion proteins in BL21
(DE3) bacterial cells and puriﬁed using standard proce-
dures. For binding assays, 0.5mg of each GST fusion pro-
tein were incubated with 2 mg biotinylated di-methylated
Lys 4, tri-methylated Lys 4, di-methylated Lys 9 or unmo-
diﬁed histone H3 peptides (Upstate), in a 200 ml reaction
using 156 ml of interaction buﬀer (20mM HEPES pH 7.5,
500mM NaCl, 1mM EDTA, 0.2% (v/v) NP-40, 0.25%
BSA and protease inhibitors), for 2 h at 48C with rotation.
Then, 15 ml Dynabeads M-280 Streptavidin (Dynal
Biotech) were added to the samples for an additional
hour and, after three washes in interaction buﬀer, each
one was eluted with 20 ml Laemmli buﬀer 2 and sub-
jected to western blot analysis using an a-GST antibody.
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RESULTS
Depletion of CHD8 impairs cell proliferation
In order to identify CHD8 functions we decided to
decrease the expression of CHD8 by a doxycycline-
regulated inducible shRNA expression vector (34). For
that, two knockdown stable cell lines (C33KD1 and
C33KD2) were derived from human C33A cervical carci-
noma cells. Both lines showed a signiﬁcant reduction in
the level of CHD8 expression upon doxycycline (Dox)
addition (85% reduction after 72 h), as determined by
immunoblotting (Figure 1A). RT–PCR experiments
demonstrated that expression of the closely related para-
logous genes CHD6, CHD7 and CHD9 was unaﬀected,
indicating that the knockdown was speciﬁc (Supplemen-
tary Figure S1). To determine whether reduced CHD8
levels aﬀect cell proliferation, the growth rate of
C33KD1 and C33KD2 cell lines was studied in the pres-
ence or the absence of Dox. Both cell lines exhibited a
slower growth rate under conditions of CHD8 depletion,
indicating that CHD8 is required for C33A cell prolifera-
tion (Figure 1B). As a control, we veriﬁed that Dox had no
eﬀect on the growth rate of C33A cells (data not shown).
To extend our results to another cell line we generated
knockdown HeLa clones that showed identical defects in
proliferation under conditions of CHD8 depletion
(Supplementary Figures S2A and B). FACS analysis of
proliferating C33KD1 and C33KD2 cells demonstrated
that knockdown of CHD8 reduced the S-phase cell pop-
ulation from 40% to 32%, with a concomitant increase
in the G1 cell population from about 40–50%. Meanwhile,
the G2/M cell population remained essentially unchanged
(Figure 1C). Consistently, BrdU incorporation experi-
ments revealed that upon a 15-min pulse of BrdU
Figure 1. Depletion of CHD8 impairs cell proliferation. CHD8 shRNA knockdown cell lines (C33KD1 and C33KD2) were generated by stable
transfection of C33A cells. (A) Immunoblot analysis of Dox-treated (+) and non-treated () cells after 72 h, using a-CHD8 antibody. a-Ser2-P
RNAPII antibody (H5) was used as a loading control. (B) Growth curve of CHD8 knockdown cell lines in the presence or absence of Dox. Data are
the average of three independent experiments. Error bars represent standard deviation. (C) Flow cytometry analysis of asynchronous C33KD1 and
C33KD2 cells treated with or without Dox for 72 h. Representative experiments are shown. Numbers are the average of three independent experi-
ments. (D) BrdU incorporation analysis of cycling cells. C33KD1 and C33KD2 cells treated or non-treated with Dox for 48 and 72 h were labeled
with BrdU as described in Methods. Percentage of cells that had incorporated BrdU was determined by immunoﬂuorescence using a-BrdU
antibodies. Numbers are the average of two independent experiments.
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around 50% of the cells were able to incorporate BrdU in
the absence of Dox but only about 35% of the
CHD8-depleted cells were BrdU-positive (Figure 1D).
These data suggest that CHD8 positively regulates the
cell cycle by facilitating the G1/S transition.
CHD8 contributes to the expression ofCCNE2 and
TYMS genes
To identify CHD8 target genes we compared the genome-
wide expression proﬁling of C33KD2 cells after Dox addi-
tion with that of non-treated cells. For this purpose, cells
were collected after only 48 h of Dox treatment, when
CHD8 levels were about 40% of its original quantity
(data not shown). This was thought to avoid secondary
eﬀects produced by a pronounced growth arrest and to
increase the probability of identifying direct target genes.
Three independent biological replicates were performed.
Taking into consideration only transcripts with a
log2(+Dox/–Dox expression ratio) >0.5 or <0.5, with
statistically signiﬁcant P values 0.01, 10 and 31 genes
were found to be up-regulated and down-regulated,
respectively, in CHD8-depleted cells compared to non-
depleted cells (Supplementary Table S1). As expected,
levels of the CHD8 transcript were down-regulated in
the CHD8-depleted cells. Eﬃciency of the microarray-
based identiﬁcation of CHD8-dependent genes was con-
ﬁrmed by RT–PCR analyses of a subset of misregulated
genes (Supplementary Figure S3). Given the cell-cycle pro-
gression defects observed in the CHD8-depleted cells, we
speciﬁcally focused on the cell-cycle-related genes among
the CHD8-dependent ones. Interestingly, cyclin E2
(CCNE2) and thymidylate synthetase (TYMS), two
E2F1-dependent genes expressed during the G1/S transi-
tion (41), were found to be down-regulated in
CHD8-depleted cells (Figure 2A, B and C and Table 1).
As a control, we veriﬁed that the expression of these two
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Figure 2. Depletion of CHD8 leads to down-regulation of TYMS and CCNE2 genes. (A) Transcript levels of genes induced at the G1/S transition
(TYMS, CCNE2, CCNE1, CCNA2, TK1) were analyzed by RT–PCR in Dox-treated (+) or non-treated () C33KD2 cells, at the indicated times. b-
Actin (ACTB) transcript levels were also determined as a control for the amount of input cDNA. (B) Quantiﬁcation of signals shown in (A). Values
were normalized to the ACTB gene transcript level. The level of cDNA ampliﬁed in Dox non-treated cells () was considered 100%. Values are the
average of three independent experiments. Bars indicate standard error of the mean. (C) Levels of CHD8, CCNE2, E2F1 and PCNA proteins were
analyzed by immunoblot in C33KD2 cells treated (+) or non-treated () with Dox during the indicated time. a-Ser2-P-RNAPII antibody (H5) was
used as a loading control. (D) The CCNE2 promoter is activated by CHD8. COS-7 cells were transfected with 0.2 mg of pCycE2-LUC plasmid along
with 0.3 or 0.7 mg of pRSV-CHD8 plasmid. 0.2 mg of the pMMTV-LUC plasmid were co-transfected with a glucocorticoid receptor expression vector
(0.2 mg) and with or without 0.7 mg of pRSV-CHD8. When indicated, the glucocorticoid receptor ligand dexamethasone (DEX) was added at 1mg/ml
for 12 h. Values are the average of three independent experiments  SD.
Nucleic Acids Research, 2009, Vol. 37, No. 8 2453
genes was not aﬀected by Dox in C33A cells (data not
shown). These results led us to explore the possibility
that other genes speciﬁcally expressed in the G1/S
cell-cycle transition were also misregulated in CHD8-
depleted cells. Expression of none of the tested genes
(CCNE1, cyclin E1; CCNA2, cyclin A; TK1, thymidine
kinase; E2F1 or PCNA) was found to be signiﬁcantly
altered upon Dox addition (Figure 2A, B and C) indicat-
ing that the reduction in the amount of CCNE2 and
TYMS transcripts is not a consequence of the G1 arrest
provoked by the depletion of CHD8. Down-regulation of
cyclin E2 was also veriﬁed using two independent shRNAs
targeting two diﬀerent regions of the CHD8 mRNA
(Supplementary Figure S4), as well as in CHD8-depleted
HeLa cells (Supplementary Figure S2C).
To verify whether CCNE2 is a direct target of CHD8,
a promoter-reporter construct was co-transfected with
increasing quantities of a CHD8 expression vector and
the expression of the luc reporter gene was determined.
As shown in Figure 2D, CHD8 stimulated about 4-fold
the activity of the promoter. As a negative control, CHD8
was not able to activate the MMTV promoter either in the
absence or in the presence of dexamethasone, its inductor.
To further investigate whether CCNE2 and TYMS are
direct targets of CHD8 in vivo, we performed chromatin
immunoprecipitation (ChIP) assays in C33A cells.
Figure 3A shows that CHD8 binds to the 50 region of
these genes. Depletion of CHD8 upon Dox addition
to C33KD2 cells led to a signiﬁcant reduction in the
amount of immunoprecipitated CCNE2 and TYMS chro-
matin, which conﬁrms the speciﬁcity of the a-CHD8 anti-
bodies in our ChIP assays (Figure 3B and C). Next, we
decided to investigate the precise location of CHD8 within
the CCNE2 gene. As shown in Figure 3D, CHD8 was
enriched in the promoter and the transcribed 50 region
of the gene.
CCNE2 is an E2F-dependent gene transcriptionally
active only during the G1/S and S phase fractions of the
cell cycle (41,42) (Figure 4B and C). Thus, we wondered
whether the association of CHD8 with the CCNE2 gene
was cell-cycle-regulated. For that, we synchronized HeLa
cells in G1/S by double thymidine blocking and performed
ChIP experiments at diﬀerent cell-cycle stages obtained
by diﬀerential timed release in normal media. Given
our interest in the G1/S transition, we used cell popula-
tions synchronized at early G1, late G1, G1/S and S
(Figure 4A). As shown in Figure 4B and C, while the
levels of CHD8 were not aﬀected by the cell cycle,
CCNE2 was only expressed at the G1/S and S fractions.
ChIP experiments evidenced that CHD8 remains bound to
the CCNE2 gene during the entire cell cycle (Figure 4D).
Interestingly, a constitutive RNAPII occupancy at the
CCNE2 promoter-proximal region was also observed
(Figure 4E), suggesting that RNAPII is paused at the
CCNE2 gene during both early and late G1 fractions,
when the gene is not transcriptionally active (Figure 4B
and C). However, a signiﬁcant increase of RNAPII occu-
pancy in the promoter and in body of the gene was
observed at the G1/S transition coincident with the acti-
vation of the gene (Figure 4E).
The tandem chromodomains of CHD8 bind H3K4me2
in vitro
CHD8 contains two chromodomains (CDs) within its
amino-terminal half. Chromodomains have been shown
to mediate interactions of chromatin factors with methy-
lated lysines of the histone tails. In fact, the similar CHD1
Table 1. Selection of up- and down-regulated transcripts in CHD8-depleted cells
Gene symbol Gene product description Fold change
Up-regulated genes
CSH1 Chorionic somatomammotropin hormone 1 2.7321
NUPL1 Nucleoporin like 1 1.8661
DKFZp451J1719 YOD1 deubiquinating enzyme 1 homolog 1.8150
ARHGEF12 Rho guanine nucleotide exchange factor (GEF) 12 1.6586
CRADD CASP2 and RIPK1 domain containing adaptor with death domain 1.5052
RASA2 RAS p21 protein activator 2 1.4044
Down-regulated genes
CDK2AP1 CDK2-associated protein 1 0.71203
DHX29 DEAH (Asp-Glu-Ala-His) box polypeptide 29 0.70222
USP11 Ubiquitin speciﬁc protease 11 0.69737
KLF13 Kruppel-like factor 13 0.69737
NUCKS Nuclear ubiquitous casein kinase and cyclin-dependent kinase substrate 0.69255
ROR1 Receptor tyrosine kinase-like orphan receptor 1 0.67830
CCNE2 Cyclin E2 0.67362
KLF15 Kruppel-like factor 15 0.66896
PORIMIN Pro-oncosis receptor inducing membrane injury gene 0.66896
ZNF655 Zinc ﬁnger protein 655 0.66896
AGPAT3 1-Acylglycerol-3-phosphate O-acyltransferase 3 0.64171
CHD8 Chromodomain helicase DNA binding protein 8 0.63728
NIN Ninein (GSK3B interacting protein) 0.62417
TYMS Thymidylate synthetase 0.61132
CRISP3 Cysteine-rich secretory protein 3 0.52851
KIN KIN antigenic determinant of recA protein homolog 0.35111
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tandem chromodomains bind histone H3 tri-methylated in
lysine 4 (43,44). Therefore, we decided to investigate
whether the tandem CDs of CHD8 directly bind methy-
lated H3K4, in vitro. For that, its ﬁrst (CD1), second
(CD2) or tandem chromodomains (CD1+CD2)
(Figure 5A) were expressed in Escherichia coli as GST-
fusion proteins. Recombinant puriﬁed proteins were incu-
bated with biotinylated peptides corresponding to the ﬁrst
21 amino acids of histone H3, either unmodiﬁed or mod-
iﬁed by methylation in lysine 4 (di-methylated or tri-
methylated) or in lysine 9 (di-methylated). Figure 5B
shows that while CD1 was unable to interact with any
histone H3 peptide, CD2 bound the four peptides without
signiﬁcant preference. More importantly, the tandem
chromodomains mostly interacted with the H3K4me2
peptide. Single chromodomain proteins bind to methyl-
ated lysines by interaction with several aromatic residues
(aromatic cage) (28). Thus, mutation of the conserved
aromatic residues W751 and Y756 of CD2 completely
abolished the binding activity of the tandem chromodo-
mains. However, a triple mutation of the conserved aro-
matic residues (Y672L, Y675L, Y677L) of CD1 does not
aﬀect the binding. Therefore, our data suggest that CD1
contribution to the binding speciﬁcity does not require its
aromatic cage. This is consistent with data from the
human CHD1 protein, where the H3-methylated peptide
interacts with an acidic surface bridging chromodomains 1
and 2 (44). These data suggest a possible role of H3K4me2
in recruiting CHD8 to the chromatin. However, further
in vivo experiments are required to conﬁrm this hypoth-
esis. Then we decided to investigate whether the level of
CHD8 aﬀects the degree of methylation of histone H3 in
the CCNE2 gene. ChIP experiments demonstrated that
histone H3 is di- and tri-methylated in lysine 4 in the
CCNE2 promoter and 50 transcribed region, irrespectively
of the levels of CHD8 (Figure 5C), indicating that CHD8
is not required for H3K4 methylation at the CCNE2 gene.
CHD8 associates with phosphorylated RNAPII
As a ﬁrst step in the characterization of the mechanism
by which CHD8 controls gene expression we investi-
gated whether CHD8 interacts with RNAPII. When
recruited to promoters, the CTD of the largest
subunit of RNAPII is unphosphorylated (RNAPIIa).
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After promoter clearance and during early stages of elon-
gation, ﬁrstly serine 5 (Ser5) and subsequently serine 2
(Ser2) are phosphorylated (Ser5-P and Ser2-P)
(RNAPIIo) (45). The 8WG16 antibody recognizes
mostly unmodiﬁed CTD repeats and some intermediate
phosphorylated forms (46), while antibodies H14
and CTD4H8 recognize Ser5-P CTD and antibody H5
recognizes Ser2-P CTD repeats. In contrast, antibody
N20 recognizes all RNAPII forms. Interestingly, CHD8
co-immunoprecipitated with hyperphosphorylated
RNAPIIo complexes enriched for Ser5-P and Ser2-P
(Figure 6A). However, CHD8 did not co-immunoprecipi-
tate with the transcription elongation factor SPT5 or with
the HMG protein BRAF35 (Figure 6A).
The fact that CHD8 associates with the elongating
forms of RNAPII suggested that CHD8 might have a
role in elongation. To support this hypothesis we asked
whether CHD8-depleted cells were hypersensitive to
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inhibitors of transcription elongation. We reasoned that if
elongation of some genes is altered in CHD8-depleted
cells, a partial inhibition of elongation should enhance
the eﬀect of CHD8 depletion provoking a synthetic phe-
notype. Indeed, CHD8-depleted cells were hypersensitive
to low concentrations of ﬂavopiridol or 5,6-dichloro-1-
b-D-ribofuranosylbenzimidazole (DRB), two drugs that
impair elongation by inhibiting CDK9, a component of
the P-TEFb complex (47–49) (Figure 6B and C).
DISCUSSION
Here we show that CCNE2 is a direct target of CHD8.
A number of results support this conclusion. First,
CHD8-depleted cells present decreased levels of the
CCNE2 transcript and its protein. Second, CHD8 trans-
activates the CCNE2 promoter in transient transfection
experiments. And third, CHD8 binds directly to the
CCNE2 gene in vivo. We also provide several lines of
evidence suggesting that CHD8 plays a positive role in
the ﬁrst steps of RNAPII elongation. First, CHD8
co-immunoprecipitates with RNAPII phosphorylated
in serines 5 and 2 of its CTD, but not with non-
phosphorylated RNAPII. Similarly to CHD8, other typi-
cal elongating factors such as Spt6, DSIF and the PAF
complex associate with elongating RNAPII (50–52).
Second, ChIP experiments demonstrate that CHD8
binds not only to the promoter but also to the pro-
moter-proximal transcribed region of the CCNE2 gene.
In the same way, but unlike initiation factors, elongation
factors such as DSIF, Spt6, TREX and PAF complexes
associate with the coding region of active genes (53–55).
Third, CHD8-depleted cells are hypersensitive to ﬂavo-
piridol and DRB, drugs that provoke RNAPII arrest by
inhibiting RNAPII CTD phosphorylation at serine 2
(56,57). The fact that CHD8-depleted cells are hypersen-
sitive to both inhibitors suggests that CHD8 acts in the
same process that is being inhibited by the drugs.
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Although these experiments suggest a role for CHD8
during the ﬁrst steps of elongation, we can not rule out
an additional role for this factor in the formation of the
pre-initiation complex.
As deﬁned by Flaus et al., the ATPase CHD8 belongs to
the CHD7 subfamily of the SNF2 family (5). In addition
to CHD8, other three proteins belong to this subfamily in
mammals: CHD6, CHD7 and CHD9. In contrast, only
one protein called Kismet belongs to this subfamily in
Drosophila. The kismet gene was originally identiﬁed as
a suppressor of Polycomb mutations and, therefore,
belongs to the trithorax group of genes (58). Kismet has
been shown to play important roles in both segmentation
and determination of body segment identity (59), and was
found to co-localize with almost all RNAPII sites (60). kis
mutants display a dramatic reduction in the levels of both
CTD-Ser2 phosphorylated RNAPII and the elongation
factors dSPT6 and dCHD1 on polytene chromosomes,
suggesting that Kismet is required for transcription
elongation (60). In contrast to kis mutations, CHD8
depletion does not generally reduce the levels of
Ser2-phosphorylated RNAPII (Figure 1). One possibility
is that the function that Kismet performs in Drosophila is
carried out in mammals by several members of the sub-
family (CHD6 to CHD9). This would explain why the
depletion of only one member of the subfamily does not
have a general eﬀect, but a gene-speciﬁc eﬀect. This is
consistent with our whole genome expression analysis, as
only a small number of genes were found to be misregu-
lated upon knocking down CHD8.
While preparing the revised version of this manuscript it
has been reported that loss of Kismet function leads to a
reduction in the level of the H3K4 methyl transferases
TRX and ASH1 on polytene chromosomes (61). In
agreement with the hypothesis that CHD8 and Kismet
are functional orthologs, it has been shown that CHD8
co-puriﬁes with components of the MLL1 (mixed-lineage
leukemia) complex (31,62), the mammalian TRX
homolog. Moreover, and consistently with what we
describe for CHD8, MLL1 has been found to interact
with elongating RNAPII and bind to the promoters and
50 transcribed regions of the genes. However, while MLL1
mostly associates with transcriptionally active genes,
CHD8 binds to the CCNE2 gene under conditions of
both activation and repression. Furthermore, depletion
of CHD8 does not aﬀect the levels of H3K4me2 or
H3K4me3, suggesting that CHD8 does not cooperate
with the MLL1 complex for histone H3K4 methylation.
Interestingly, Srinivasan et al. (61) have also shown that,
despite the reduced recruitment of TRX and ASH1, the
loss of Kismet has no eﬀect on the level of H3K4 methyla-
tion on polytene chromosomes or over the fkh gene. The
connection between H3K4 histone methyl transferases
and Kismet/CHD8 proteins requires further investigation.
The way CHD8 is recruited to its target genes remains
unknown. One possibility is that some speciﬁc histone
modiﬁcations contribute to the recruitment of CHD8.
Here we demonstrate that, in contrast to Drosophila
Kismet (61), CHD8 directly binds in vitro to H3K4me2
through its tandem chromodomains. Consistently with
our results, Yuan et al. recently used fractions enriched
for CHD8 to demonstrate its direct or indirect association
with di- and tri-methylated lysine 4 of histone H3 amino-
terminal peptides (63). We also found that CHD8 is con-
stitutively bound to the CCNE2 gene, even during G1,
when the gene is not active. This is also consistent with
the fact that CHD8 interacts with histone H3K4me2
in vitro, since H3K4me3 correlates with actively tran-
scribed genes while H3K4me2 can be present on poised,
inactive genes (64,65). Interestingly we also found signiﬁ-
cant levels of RNAPII associated to the CCNE2 gene
under conditions of repression. Promoter-proximal paus-
ing (1) is a widespread phenomenon that takes place in
many genes, where RNAPII pauses in the 50 region of
transcription units and only progresses into productive
elongation upon stimulation by appropriate signals.
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Paused RNAPII is phosphorylated at serine 5 of its CTD.
The association of CHD8 with the repressed CCNE2 gene
and the fact that it interacts with Ser5-P-RNAPII suggest
that CHD8 might be recruited to genes having paused
RNAPII.
CHD8 may also be recruited to its targets by interaction
with speciﬁc transcription factors. In fact, it has been
shown that CHD8 associates with human staf/ZNF143,
a zinc ﬁnger protein that controls the expression of the
U6 gene (63), and with b-catenin (31). In this respect we
found that, although CHD8 is required for normal expres-
sion of CCNE2 and TYMS, two G1/S-speciﬁc genes
which are targets of the E2F1 transcription factor (41),
the expression of other typical E2F1-dependent genes
such as CCNE1, CCNA2, TK1, PCNA or E2F1 itself
did not change signiﬁcantly under conditions of CHD8
depletion. Nonetheless and interestingly, we have veriﬁed
the presence of CHD8 in the 50 region of CCNE1 and TK1
by ChIP experiments (data not shown). Furthermore, in
transient transfection experiments CHD8 was also able to
activate the expression of a minimal promoter containing
an E2F1 synthetic binding site (data not shown). One pos-
sibility is that E2F1 could recruit CHD8 to all E2F1-
dependent genes but that only those genes with a speciﬁc
chromatin structure at the 50 region require CHD8 for
normal elongation. Therefore, we suggest that the speciﬁ-
city of CHD8 for a subset of genes may involve its inter-
action with speciﬁc transcription factors, speciﬁc histone
modiﬁcations and the phosphorylation status of RNAPII.
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